Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




First-Ever Test of Cure for Chagas Disease Determines Treatment Effectiveness

By LabMedica International staff writers
Posted on 25 Jun 2025

An estimated 6 to 8 million individuals across the globe are infected with Trypanosoma cruzi, the parasite responsible for Chagas disease, which claims over 10,000 lives annually. More...

This disease doesn’t just affect humans; numerous mammals, including wildlife and domestic dogs, are also susceptible to infection. In current drug trials, clinicians can only determine when a treatment has failed. There remains a pressing need for a reliable test of cure—one that can confirm whether a drug has successfully eliminated the infection. A major challenge in confirming the effectiveness of treatment is that the immune system often keeps the infection under control, making parasite levels undetectable by existing tests due to their limited sensitivity. A new test protocol now offers the ability to detect low levels of T. cruzi, enabling accurate diagnosis in monkeys, dogs, and humans.

Researchers at the University of Georgia’s Center for Tropical and Emerging Global Diseases (Athens, GA, USA) performed extensive PCR testing on samples from naturally infected macaque monkeys, dogs, and humans. To improve detection, the team fragmented the DNA, helping it distribute more evenly within the sample—a step not included in standard PCR testing. The macaques, infected in a manner consistent with human and canine transmission, were monitored monthly over a year. A subset also underwent additional testing, with samples collected seven times in four weeks. Alongside PCR, researchers cultivated T. cruzi from blood samples, validating that the new protocol can detect infections even when parasite levels are extremely low. Given the similar disease progression in macaques, humans, and dogs, the researchers are confident that this method is broadly applicable across species.

Comparable results were observed when the protocol was applied to samples from naturally infected dogs and humans. The development of new drug treatments for Chagas disease is urgently needed, yet without an effective test of cure, researchers can only identify treatments that fail. Although the new protocol proves effective, it is also resource-intensive and time-consuming, making it expensive. To address this, the researchers explored technologies aimed at speeding up the process and reducing costs. They are currently developing a method that allows for the analysis of larger samples more quickly. Enhancing speed and cost-efficiency significantly increases the likelihood that the test can be adopted in clinical environments.

“This test of cure is a real game changer for drug treatment studies,” said Brooke White, lead researcher of the study. “We are already working with other research groups in hopes of creating a quicker and cheaper method of testing parasite load in their drug treatment studies in macaques, dogs and humans.”

Related Links:
Center for Tropical and Emerging Global Diseases


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.